Published in Br J Pharmacol on August 01, 1989
Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol (1990) 8.85
L-NG-nitro arginine (L-NOARG), a novel, L-arginine-reversible inhibitor of endothelium-dependent vasodilatation in vitro. Br J Pharmacol (1990) 7.27
Microvascular angina and the continuing dilemma of chest pain with normal coronary angiograms. J Am Coll Cardiol (2009) 2.58
L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest (1992) 2.35
Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood (2007) 2.31
Effects of inhaled nitric oxide on regional blood flow are consistent with intravascular nitric oxide delivery. J Clin Invest (2001) 2.03
Regulation of gastric mucosal integrity by endogenous nitric oxide: interactions with prostanoids and sensory neuropeptides in the rat. Br J Pharmacol (1990) 1.93
An endothelium-derived hyperpolarizing factor distinct from NO and prostacyclin is a major endothelium-dependent vasodilator in resistance vessels of wild-type and endothelial NO synthase knockout mice. Proc Natl Acad Sci U S A (2000) 1.89
Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest (1995) 1.69
Tumor necrosis factor alpha activates soluble guanylate cyclase in bovine glomerular mesangial cells via an L-arginine-dependent mechanism. J Exp Med (1990) 1.62
St Cyres lecture. Endothelium in control. Br Heart J (1991) 1.43
Evidence that nitric oxide is an endogenous antiangiogenic mediator. Br J Pharmacol (1994) 1.39
Peroxynitrite induces both vasodilatation and impaired vascular relaxation in the isolated perfused rat heart. Proc Natl Acad Sci U S A (1994) 1.29
In vivo induction of nitrite and nitrate by tumor necrosis factor, lymphotoxin, and interleukin-1: possible roles in malaria. Infect Immun (1992) 1.21
L-arginine normalizes endothelial function in cerebral vessels from hypercholesterolemic rabbits. J Clin Invest (1991) 1.15
Induction of myocardial nitric oxide synthase by cardiac allograft rejection. J Clin Invest (1994) 1.13
Adventures in vascular biology: a tale of two mediators. Philos Trans R Soc Lond B Biol Sci (2006) 1.10
Inhibitors of nitric oxide synthetase prevent castor-oil-induced diarrhoea in the rat. Br J Pharmacol (1993) 1.10
Direct evidence of nitric oxide release from neuronal nitric oxide synthase activation in the left ventricle as a result of cervical vagus nerve stimulation. J Physiol (2009) 1.08
Regulation of L-arginine transport and nitric oxide release in superfused porcine aortic endothelial cells. J Physiol (1996) 1.04
Coronary vasoconstriction in the conscious rabbit following intravenous infusion of L-NG-nitro-arginine. Br J Pharmacol (1991) 1.02
Nitric oxide. Ann Rheum Dis (1996) 0.99
Selective inhibition of basal but not agonist-stimulated activity of nitric oxide in rat aorta by NG-monomethyl-L-arginine. Br J Pharmacol (1993) 0.97
Role of basal release of nitric oxide on coronary flow and mechanical performance of the isolated rat heart. J Physiol (1992) 0.96
Coronary vasodilatation induced by endotoxin in the rabbit isolated perfused heart is nitric oxide-dependent and inhibited by dexamethasone. Br J Pharmacol (1991) 0.96
Characterization of the effects of two new arginine/citrulline analogues on constitutive and inducible nitric oxide synthases in rat aorta. Br J Pharmacol (1995) 0.90
Analysis of the depressant effect of the endothelium on contractions of rabbit isolated basilar artery to 5-hydroxytryptamine. Br J Pharmacol (1992) 0.87
Endothelial dysfunction in the coronary microcirculation: a new clinical entity or an experimental finding? J Clin Invest (1993) 0.87
N-nitro L-arginine causes coronary vasoconstriction and inhibits endothelium-dependent vasodilatation in anaesthetized greyhounds. Br J Pharmacol (1991) 0.86
Risk factors for persistent pulmonary hypertension of the newborn. Pulm Circ (2012) 0.86
Role of NO synthase in the development of Trypanosoma cruzi-induced cardiomyopathy in mice. Am J Trop Med Hyg (2009) 0.85
Coronary microcirculation: autoregulation and metabolic control. Basic Res Cardiol (1995) 0.84
Regional coronary haemodynamic effects of two inhibitors of nitric oxide synthesis in anaesthetized, open-chest dogs. Br J Pharmacol (1991) 0.82
Myogenic and flow-dependent control mechanisms in the coronary microcirculation. Basic Res Cardiol (1993) 0.82
Voltage-dependent anion channel-2 interaction with nitric oxide synthase enhances pulmonary artery endothelial cell nitric oxide production. Am J Respir Cell Mol Biol (2012) 0.82
Bacterial endotoxin rapidly stimulates prolonged endothelium-dependent vasodilatation in the rat isolated perfused heart. Br J Pharmacol (1993) 0.82
The involvement of the endothelium in the relaxation of the leopard frog (Rana pipiens) aorta in response to acetylcholine. Br J Pharmacol (1996) 0.81
In vivo experimental evidence that the nitric oxide pathway is involved in the X-ray-induced antiangiogenicity. Br J Cancer (1996) 0.80
Impaired vascular sensitivity to nitric oxide in the coronary microvasculature after endotoxaemia. Br J Pharmacol (2000) 0.80
Nitric oxide is an important determinant of coronary flow in the isolated blood perfused rat heart. Basic Res Cardiol (1993) 0.80
Mechanisms of coronary vasodilatation produced by ATP in guinea-pig isolated perfused heart. Br J Pharmacol (1992) 0.80
L-arginine induces relaxation of rat aorta possibly through non-endothelial nitric oxide formation. Br J Pharmacol (1991) 0.78
Release of endothelial mediators and sympathetic transmitters at different coronary flow rates in rabbit hearts. J Physiol (1991) 0.77
The effects of perfusion rate and NG-nitro-L-arginine methyl ester on cirazoline- and KCl-induced responses in the perfused mesenteric arterial bed of rats. Br J Pharmacol (1994) 0.77
Effect of inhaled nitric oxide on intrapulmonary right-to-left-shunting in two rabbit models of saline lavage induced surfactant deficiency and meconium instillation. Eur J Pediatr (1998) 0.77
Comparison of the ability of nicardipine, theophylline and zaprinast to restore cardiovascular haemodynamics following inhibition of nitric oxide synthesis. Br J Pharmacol (1994) 0.76
Relation between plasma nitrate and mean pulmonary arterial pressure in ventricular septal defect. Arch Dis Child (1998) 0.75
Effect of methylguanidine on rat blood pressure: role of endothelial nitric oxide synthase. Br J Pharmacol (1995) 0.75
The vasoconstrictor effects of L-NAME, a nitric oxide synthase inhibitor, in pregnant rabbits. Br J Pharmacol (1996) 0.75
Attenuation by creatine of myocardial metabolic stress in Brattleboro rats caused by chronic inhibition of nitric oxide synthase. Br J Pharmacol (1995) 0.75
The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (1980) 40.02
Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 35.44
Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (1988) 18.41
Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A (1989) 8.34
L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun (1988) 7.77
A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol (1989) 6.30
The nature of endothelium-derived vascular relaxant factor. Nature (1984) 5.53
Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol (1986) 4.23
Identification of arginine as a precursor of endothelium-derived relaxing factor. Proc Natl Acad Sci U S A (1988) 3.44
Arginine is a physiological precursor of endothelium-derived nitric oxide. Eur J Pharmacol (1988) 3.24
Preparation and characterization of Ng-mono-, di- and trimethylated arginines. Acta Biochim Biophys Acad Sci Hung (1977) 2.62
Acetylcholine induces vasodilatation in the rabbit isolated heart through the release of nitric oxide, the endogenous nitrovasodilator. Br J Pharmacol (1988) 2.32
Chronic treatment with SCH 23390, a selective dopamine D-1 receptor antagonist, decreases dopamine metabolism in rat caudate nucleus. Eur J Pharmacol (1988) 1.45
Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev (1991) 42.38
Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (1987) 35.44
Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (1988) 18.41
An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature (1976) 13.19
Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature (1986) 9.93
Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol (1990) 8.85
Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A (1989) 8.34
Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase. Proc Natl Acad Sci U S A (1989) 7.79
L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun (1988) 7.77
Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet (1989) 7.69
Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochem Pharmacol (1989) 6.87
Nitric oxide synthases in mammals. Biochem J (1994) 6.50
A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol (1989) 6.30
Altered immune responses in mice lacking inducible nitric oxide synthase. Nature (1995) 6.20
Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization. JAMA (2001) 6.02
Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from L-arginine. J Immunol (1990) 5.87
Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat New Biol (1971) 5.62
Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet (1992) 5.36
Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol (1987) 5.23
A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem Biophys Res Commun (1989) 5.14
The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol (1987) 4.88
Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev (1978) 4.66
Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet (1987) 4.55
Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins (1976) 4.54
Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci U S A (1990) 4.49
Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins (1976) 4.44
Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol (1986) 4.23
Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett (1994) 4.19
Endothelium-derived relaxing factor. Identification as nitric oxide and role in the control of vascular tone and platelet function. Biochem Pharmacol (1988) 4.16
Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet (1977) 4.11
An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A (1990) 3.98
A randomized trial of care in a hospital medical unit especially designed to improve the functional outcomes of acutely ill older patients. N Engl J Med (1995) 3.77
Relation between symptoms of depression and health status outcomes in acutely ill hospitalized older persons. Ann Intern Med (1997) 3.76
Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins (1977) 3.74
Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis? Lancet (1978) 3.74
Synthesis of nitric oxide from L-arginine by neutrophils. Release and interaction with superoxide anion. Biochem J (1989) 3.70
The chemical structure of prostaglandin X (prostacyclin). Prostaglandins (1976) 3.63
Widespread tissue distribution, species distribution and changes in activity of Ca(2+)-dependent and Ca(2+)-independent nitric oxide synthases. FEBS Lett (1991) 3.43
Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med (1979) 3.29
Roles of nitric oxide in tumor growth. Proc Natl Acad Sci U S A (1995) 3.28
Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res (1977) 3.28
The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun (1987) 3.25
Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc Natl Acad Sci U S A (1991) 3.22
Does delirium contribute to poor hospital outcomes? A three-site epidemiologic study. J Gen Intern Med (1998) 3.21
Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature (1973) 3.20
Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res (1992) 3.15
Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem Biophys Res Commun (1990) 3.14
Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci U S A (1998) 3.10
An improved method for washing of human platelets with prostacyclin. Thromb Res (1983) 3.07
Control of regional blood flow by endothelium-derived nitric oxide. Hypertension (1990) 2.93
Functional status before hospitalization in acutely ill older adults: validity and clinical importance of retrospective reports. J Am Geriatr Soc (2000) 2.92
Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature (1976) 2.83
Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans. Biochem Biophys Res Commun (1991) 2.79
Nitric oxide from L-arginine stimulates the soluble guanylate cyclase in adrenal glands. Biochem Biophys Res Commun (1989) 2.73
Nitric oxide synthase activities in human myocardium. Lancet (1993) 2.72
Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc Natl Acad Sci U S A (1994) 2.70
Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid. Prostaglandins (1977) 2.67
Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis (1992) 2.63
Chemokinetic activity of arachidonic and lipoxygenase products on leuocyctes of different species. Prostaglandins (1980) 2.59
Rapid development of atherosclerotic lesions in the rabbit carotid artery induced by perivascular manipulation. Atherosclerosis (1989) 2.58
NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol (1989) 2.53
Arrest of preterm labour and prolongation of gestation with glyceryl trinitrate, a nitric oxide donor. Lancet (1994) 2.53
Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull (1978) 2.51
Production of hydroxyl radicals from the simultaneous generation of superoxide and nitric oxide. Biochem J (1992) 2.51
Imidazole: a selective inhibitor of thromboxane synthetase. Prostaglandins (1977) 2.48
Inhibition of nitric oxide synthesis in septic shock: how much is beneficial? Lancet (1992) 2.44
Measuring prognosis and case mix in hospitalized elders. The importance of functional status. J Gen Intern Med (1997) 2.42
S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol (1992) 2.39
The role of TH1 and TH2 cells in a rodent malaria infection. Science (1993) 2.38
Modulation of acute inflammation by endogenous nitric oxide. Eur J Pharmacol (1992) 2.32
Acetylcholine induces vasodilatation in the rabbit isolated heart through the release of nitric oxide, the endogenous nitrovasodilator. Br J Pharmacol (1988) 2.32
Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages. Biochem Biophys Res Commun (1990) 2.31
Anti-inflammatory glucocorticoids inhibit the induction by endotoxin of nitric oxide synthase in the lung, liver and aorta of the rat. Biochem Biophys Res Commun (1990) 2.31
A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins (1976) 2.28
Nitric oxide synthase activity in human gynecological cancer. Cancer Res (1994) 2.27
Inhibition of nitric oxide synthase as a potential therapeutic target. Annu Rev Pharmacol Toxicol (1999) 2.26
Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature (1980) 2.24